Progress in the pathogenesis and treatment of Trousseau syndrome-related ischemic stroke
In recent years,with the increasing incidence of cancer,Trousseau syndrome(TS)-related ischemic stroke showed an increasing trend year by year,resulting in a high disability rate,high mortality,and a high short-term recurrence rate,resulting in serious consequences.The pathogenesis is complex and unclear,and hypercoagulability is considered to be the main pathogenesis.Non-bacterial endocarditis,anticancer therapy,vascular endothelial injury,and hemodynamic changes are all related to the occurrence of the disease.At present,there is no unified standard for the treatment of TS-related ischemic stroke at home and abroad,and anticoagulation is recommended for the early and long-term treatment of this disease.There are many types of anticoagulant drugs with complex mechanisms of action,but there is no clear clinical guideline for the selection of anticoagulant drugs in China,and thrombolytic therapy can reduce the disability rate in the case of non-contraindications in the very early stage,so it is an acceptable treatment for the acute stage of this disease.The long-term benefits of thrombolytic therapy need to be confirmed by large sample clinical evidence.
NETL
NSTL
万方数据
